CHF Solutions Announces Presentation of Clinical Data with Aquadex FlexFlow® Highlighting Efficacy and Simplicity of Use In ...
January 08 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced results from an
investigator-initiated retrospective analysis of utilization of the
Aquadex FlexFlow aquapheresis system at Lenox Hill Hospital in New
York City. The study was presented at the American Society of
Nephrology’s Kidney Week in Washington, D.C. in November 2019.
“We have found that aquapheresis with Aquadex FlexFlow can be
safely utilized in situations other than diuretic resistant heart
failure, such as critical care in patients experiencing cardiogenic
shock, anasarca, ATN with fluid overload, ESRD with bridge
ultrafiltration between hemodialysis treatment, and post-op volume
overload,” said Dr. Maria V. DeVita, Nephrologist, Lenox Hill
Hospital. “Because the Aquadex FlexFlow system is safe and easy to
use when compared to more complex hemodialysis systems, these
patients were treated in different critical care settings including
the cardiothoracic ICU, CCU, medical ICU and the post-op ICU.”
“These results continue to support our assertion that the
Aquadex FlexFlow system is a key component in cardiorenal care.
This analysis from a leading center in New York City is further
validation of this assertion,” said John Erb, CEO of CHF Solutions.
“We are extremely pleased with the feedback we consistently receive
from healthcare providers on the benefits of aquapheresis with the
Aquadex FlexFlow system to manage fluid volume in a variety of
contexts.”
The analysis looked at 23 patients who received aquapheresis
treatment following cardiogenic shock, including post
cardiothoracic procedure, anasarca, acute tubular necrosis (ATN)
with volume overload, bridge ultrafiltration in end-stage renal
disease (ESRD) between hemodialysis, and post-operative volume
overload. The average duration of treatment with Aquadex FlexFlow
per patient was 4.26 days. Researchers noted that, despite the
significant volume removed per day (1,954 mls) and per encounter
(8,323mls), there was no significant change in creatinine (an
indicator of renal function). Investigators also noted the ease of
using the Aquadex FlexFlow system compared to the more complicated
operation of hemodialysis equipment.
About CHF SolutionsCHF Solutions, Inc. (Nasdaq:
CHFS) is a medical device company dedicated to changing the lives
of patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing, and commercializing the Aquadex FlexFlow
system for ultrafiltration therapy. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
About Aquadex FlexFlow® System The Aquadex
FlexFlow system is a clinically proven therapy that provides a
safe, effective, and predictable method of removing excess fluid
from patients suffering from fluid overload. The Aquadex FlexFlow
system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy, and for extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. The company
has submitted an application to the FDA requesting for 510(k)
clearance of the Aquadex FlexFlow system to include pediatric
patients who weigh 20kg or more. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including
without limitation, statements regarding the clinical performance
of the Aquadex FlexFlow system. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercialization strategy, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak
only as of the date when made. CHF Solutions does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024